Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CureVac (GB:0A9E)
LSE:0A9E
CureVac (0A9E) Share Price & Analysis
2 Followers
0A9E Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.23 - $12.29
Previous Close$3.06
Volume18.47K
Average Volume (3M)11.36K
Market Cap
$700.75M
Enterprise Value$247.04M
Total Cash (Recent Filing)€495.80M
Total Debt (Recent Filing)€42.09M
Price to Earnings (P/E)N/A
Beta1.27
Next Earnings
May 22, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume11,361
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside292.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
CureVac News
PremiumCompany Announcements
CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
PremiumCompany Announcements
CureVac Launches Study for H5N1 Influenza VaccinePremiumCompany Announcements
CureVac Names New Chief Business Officer
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPreliminary dose-escalation results for GBM remain on track and progress with COVID-19 and flu Phase 2 trials continues, showing promise in CureVac's pipeline.
Financial PerformanceThe company plans to streamline the organization, reducing its workforce to extend its operating runway, indicating improved financial sustainability.
Strategic PartnershipsCollaboration with MD Anderson for antigen discovery and vaccine development, with CureVac retaining exclusive rights, enhances the company's research capabilities.
Bears Say
Analyst SentimentAnalyst downgrades CVAC from Outperform to Market Perform and reduces price target from $12 to $4, citing extended timelines and restructuring efforts.
Financial HealthCVAC faces balance sheet pressure with a runway to 4Q25, which may lead to less than a year of cash on hand by the time meaningful data is available.
Market PositionUncertain competitive positioning in a declining commercial market and lack of quantitative flu data make it difficult to compare with competitors.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
1.18% Mutual Funds
1.24% Other Institutional Investors
97.58% Public Companies and
Individual Investors
0A9E FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest share price was $2.23 and its highest was $12.29 in the past 12 months.
What is CureVac’s market cap?
Currently, no data Available
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is May 22, 2024 which is in 18 days.
How were CureVac’s earnings last quarter?
Currently, no data Available
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Undervalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CureVac have?
CureVac has 223,883,090 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CureVac?
Among the largest hedge funds holding CureVac’s share is RA Capital Management. It holds CureVac’s shares valued at 12M.
---
CureVac Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (292.03% Upside)
$12.00 (292.03% Upside)
Blogger Sentiment
Neutral
GB:0A9E Sentiment 50%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.09%
12-Months-Change
Fundamentals
Return on Equity
-49.31%
Trailing 12-Months
Asset Growth
-5.18%
Trailing 12-Months
Company Description
CureVac
CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
---
0A9E Company Deck
---
0A9E Earnings Call
Q4 2024
0:00 / 0:00
---
0A9E Stock 12 Months Forecast
Average Price Target
$12.00
▲(292.03% Upside)
Technical Analysis
Best Analysts Covering 0A9E
1 Year
1 Year Success Rate
1/17 ratings generated profit
1 Year Average Return
-54.88%
reiterated a buy rating 11 months ago
Copying Zhiqiang Shu's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -54.88% per trade.
---